12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Procrit epoetin alfa hematology data

Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Product: Procrit epoetin alfa
Business: Hematology
Molecular target: Erythropoietin (EPO) receptor
Description: Recombinant erythropoietin alfa (EPO)
Indication: Treat anemia
Endpoint: NA
Status: NA
Milestone: NA
Preliminary data from an independent Cochrane meta-analysis showed that erythropoiesis-stimulating agents (ESAs),...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >